ASCO 2018: Prospective, Multinational, Observational Study of Real-World Treatment Outcomes with Pazopanib in Patients with Advanced or Metastatic Renal Cell Carcinoma (Principal Study)

Chicago, IL ( Pazopanib and Sunitinib are vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs), which are established as first-line treatment options for patients with advanced or metastatic renal cell carcinoma (RCC). Pazopanib has been approved for the treatment of patients with advanced RCC, after a publication of a randomized phase 3 trial [1], showing pazopanib having a clear benefit compared to placebo in progression free survival (PFS). Other trials, such as the COMPARZ [2] and PISCES [3] compared pazopanib to sunitinib, showing that pazopanib had non-inferior efficacy and improved quality of life. Furthermore, patients and physicians preferred pazopanib over sunitinib. [3]

ASCO 2018: SPCG-13: A Randomized Phase III Trial Between Adjuvant Docetaxel and Surveillance after Radical Radiotherapy for Intermediate and High-Risk Prostate Cancer

Chicago, IL ( Pirkko-Liisa I. Kellokumpu-Lehtinen, MD, from Finland presented the first results of the SPCG-13 phase III RCT, testing docetaxel vs surveillance among men with intermediate and high-risk prostate cancer treated with radical radiotherapy. Dr. Kellokumpu-Lehtinen noted that the hypothesis for this trial was developed secondary to:

  1. Response rates for chemotherapy in metastatic breast cancer of 40-70%, with survival benefits in the adjuvant setting
  2. Response rates for chemotherapy in metastatic colorectal cancer of 20-40%, with survival benefits in the adjuvant setting
  3. Docetaxel combined with ADT has improved OS in advanced prostate cancer [1-2]

ASCO 2018: Tailoring of Chemotherapy to Fit Patients with Metastatic Urothelial Cancer

Chicago, IL ( At the precision therapy in the treatment of advanced urothelial cancer session, Arlene Siefker-Radtke, MD, discussed systematic chemotherapy for these patients and how it best fits into the treatment paradigm. 

ASCO 2018: Accuracy of 68Ga-PSMA11 PET/CT on Recurrent Prostate Cancer: Preliminary Results from a Phase 2/3 Prospective Trial

Chicago, IL (  68Ga-PSMA11 PET/CT has emerged as one of the most important molecular imaging modalities that is changing the way we diagnose, follow and treat prostate cancer. Certainly, detection of positive lesions on PSMA PET/CT (typically in biochemically recurrent or advanced disease) occurs at much lower PSA levels than traditional bone scan or CT of the abdomen and pelvis. A recently published systematic review and meta-analysis was performed to assess the sensitivity and specificity profiles of 68Ga-PSMA11 PET/CT [1].

ASCO 2018: The PROPHECY Trial: Multicenter Prospective Trial of Circulating Tumor Cell AR-V7 Detection in Men with mCRPC Receiving Abiraterone or Enzalutamide

Chicago, IL ( AR-V7, a splice variant of the full length androgen receptor (AR), has been demonstrated to be associated with enzalutamide and abiraterone (both androgen receptor axis targeting agents) resistance, as demonstrated by Antonarakis et al.1 It is not associated with docetaxel chemotherapy resistance, as chemotherapy does not target the AR axis. Yet, it is unclear if its presence in circulating tumor cells (CTC’s) taken from blood samples is a valid predictive biomarker of clinical efficacy in men with mCRPC receiving Abi and Enza or if it is just an indicator of aggressive disease and high tumor burden.

ASCO 2018: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Randomized Phase II Trial

Chicago, IL ( Increased understanding of the genomic landscape of advanced and metastatic prostate cancer has led to potentially actionable targets. Pritchard et al.1 demonstrated that 12% of men with advanced or mPCa has germline mutations in DNA repair genes. This was irrespective of family history and age of onset. BRCA2 was most common, but there were numerous that accounted for just 1-2% of that 12%.

ASCO 2018: Overall Survival Between African-American and Caucasian Men with Metastatic Castration-Resistant Prostate Cancer

Chicago, IL ( Race and ethnicity have long been explored in the context of cancer care and prostate cancer (PCa), in particular. African-American race has been established to be associated with diagnosis at a later stage, more aggressive disease and disparities in PCa care (SEER data). These have naturally been associated with reports that have suggested that African-American (AA) men with metastatic castration-resistant prostate cancer (mCRPC) have shorter overall survival (OS) than Caucasian (C) men. However, prior published reports have been limited by small sample size. 

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.